HUE056942T2 - Pirimidin vegyület - Google Patents

Pirimidin vegyület

Info

Publication number
HUE056942T2
HUE056942T2 HUE18732930A HUE18732930A HUE056942T2 HU E056942 T2 HUE056942 T2 HU E056942T2 HU E18732930 A HUE18732930 A HU E18732930A HU E18732930 A HUE18732930 A HU E18732930A HU E056942 T2 HUE056942 T2 HU E056942T2
Authority
HU
Hungary
Prior art keywords
pyrimidine compound
pyrimidine
compound
Prior art date
Application number
HUE18732930A
Other languages
English (en)
Inventor
Tomoichi Shinohara
Shin Iwata
Kenta Arai
Nobuaki Ito
Masaki Suzuki
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of HUE056942T2 publication Critical patent/HUE056942T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HUE18732930A 2017-05-31 2018-05-31 Pirimidin vegyület HUE056942T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2017/020322 WO2018220762A1 (ja) 2017-05-31 2017-05-31 ピリミジン化合物

Publications (1)

Publication Number Publication Date
HUE056942T2 true HUE056942T2 (hu) 2022-03-28

Family

ID=62685028

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18732930A HUE056942T2 (hu) 2017-05-31 2018-05-31 Pirimidin vegyület

Country Status (24)

Country Link
US (3) US10800758B2 (hu)
EP (1) EP3630729B1 (hu)
JP (1) JP6739653B2 (hu)
KR (1) KR20200011962A (hu)
CN (1) CN110603248B (hu)
AU (1) AU2018277949B2 (hu)
BR (1) BR112019023988A2 (hu)
CA (1) CA3064176A1 (hu)
CY (1) CY1125073T1 (hu)
DK (1) DK3630729T3 (hu)
EA (1) EA038907B1 (hu)
ES (1) ES2901452T3 (hu)
HR (1) HRP20211913T1 (hu)
HU (1) HUE056942T2 (hu)
IL (1) IL270579B2 (hu)
LT (1) LT3630729T (hu)
MX (1) MX2019014384A (hu)
PH (1) PH12019502639A1 (hu)
PL (1) PL3630729T3 (hu)
PT (1) PT3630729T (hu)
SA (1) SA519410563B1 (hu)
SI (1) SI3630729T1 (hu)
TW (2) TWI808974B (hu)
WO (2) WO2018220762A1 (hu)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6870064B2 (ja) * 2018-11-30 2021-05-12 大塚製薬株式会社 ピリミジン化合物の医薬用途
WO2020111263A1 (en) * 2018-11-30 2020-06-04 Otsuka Pharmaceutical Co., Ltd. Heterocyclic compounds for the treatment of epilepsy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003249812A1 (en) * 2002-07-18 2004-02-09 Queen's University At Kingston Dihydrouracil compounds as anti-ictogenic or anti-epileptogenic agents
CA2781685C (en) * 2009-12-11 2018-09-04 Autifony Therapeutics Limited Imidazolidinedione derivatives
KR20120131161A (ko) 2010-01-25 2012-12-04 씨에이치디아이 파운데이션, 인코포레이티드 특정 키뉴레닌-3-모노옥시게나제 억제제, 그의 제약 조성물 및 사용 방법
PL2649066T3 (pl) 2010-12-06 2017-04-28 Autifony Therapeutics Limited Pochodne hydantoiny przydatne jako inhibitory KV3
CN103596943B (zh) * 2011-06-07 2016-10-12 奥蒂福尼疗法有限公司 用作kv3抑制剂的乙内酰脲衍生物
CA2841981A1 (en) * 2011-07-28 2013-01-31 Chdi Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
DK2788339T3 (en) 2011-12-06 2016-05-23 Autifony Therapeutics Ltd HYDANTOIN DERIVATIVES, USEFUL AS QU3 INHIBITORS
GB201521751D0 (en) * 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses

Also Published As

Publication number Publication date
CY1125073T1 (el) 2023-03-24
AU2018277949A1 (en) 2019-12-12
MX2019014384A (es) 2020-01-23
TWI808974B (zh) 2023-07-21
AU2018277949B2 (en) 2021-11-18
PL3630729T3 (pl) 2022-01-24
EA201992831A1 (ru) 2020-03-30
IL270579A (hu) 2019-12-31
CA3064176A1 (en) 2018-12-06
WO2018220762A1 (ja) 2018-12-06
HRP20211913T1 (hr) 2022-03-04
IL270579B1 (en) 2023-04-01
EP3630729A1 (en) 2020-04-08
WO2018221667A1 (en) 2018-12-06
JP6739653B2 (ja) 2020-08-12
EA038907B1 (ru) 2021-11-08
SI3630729T1 (sl) 2022-01-31
IL270579B2 (en) 2023-08-01
KR20200011962A (ko) 2020-02-04
EP3630729B1 (en) 2021-11-03
US20200017476A1 (en) 2020-01-16
ES2901452T3 (es) 2022-03-22
SA519410563B1 (ar) 2022-07-25
TW202346283A (zh) 2023-12-01
US20200399245A1 (en) 2020-12-24
US10800758B2 (en) 2020-10-13
PT3630729T (pt) 2021-12-16
CN110603248A (zh) 2019-12-20
BR112019023988A2 (pt) 2020-06-30
LT3630729T (lt) 2022-01-10
TW201902890A (zh) 2019-01-16
DK3630729T3 (da) 2021-12-13
PH12019502639A1 (en) 2020-06-08
JP2020503334A (ja) 2020-01-30
CN110603248B (zh) 2023-07-04
US20230138411A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
HK1255921A1 (zh) 嘧啶化合物
IL268190A (en) Quinazoline compound
GB201704325D0 (en) Compounds
GB2569388B (en) Compound
GB2569389B (en) Compound
GB201721178D0 (en) Compound
GB201721179D0 (en) Compound
GB201721180D0 (en) Compound
GB201721172D0 (en) Compound
AP2016009506A0 (en) Pyrimidine compound
EP3372588A4 (en) pyrimidine
SG10201913525QA (en) Pyrimidine derivative
GB201717051D0 (en) Compounds
GB201617103D0 (en) Compound
PL3630729T3 (pl) Związek pirymidynowy
HUE058181T2 (hu) Subsztituált guanidin vegyület
GB201709565D0 (en) Compound
GB201610497D0 (en) Compound
IL268060B (en) Phenyldifluoromethyl-substituted prolinamide compound
IL281765A (en) Aminopyrimidine compound
GB201721673D0 (en) Compound
GB201721324D0 (en) Compound
GB201703274D0 (en) Compound
GB201706323D0 (en) Compounds
GB201703273D0 (en) Compounds